# Chongqing Precision Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chongqing-precision-biotech-co

- Industry: Biotechnology
- Headquarters: Chongqing, China
- Website: www.precision-biotech.com
- Latest round: Angel (Jul 28, 2016)
- Investors on record: 2

## About

Based in Chongqing, China, and established in 2016, Chongqing Precision Biotech Co., Ltd. is a biotechnology company that focuses on the R&D and application of gene and cell drugs for cancer. The company was co-established by Scientist professor Cheng Qian and listed company Zhifei Biologicals. It has supported drug INDs and NDA R&D center covered 18, 000 square meters. It is establishing a regional cell preparation centre (RCPC), with 10 acres. In 2018, Its product pCAR-19B receives Class I new drug clinical application acceptance. In 2019, pCAR-19B first indication approved. In 2020, pCAR-19B approved for implied clinical licences for two new indications. In 2021, Completed pCAR-19B Phase I clinical trial for adult. 

The company has developed more than 10 product pipelines, including leukemia, lymphoma, myeloma, kidney cancer, rectal cancer, lung cancer and breast cancer. It uses the immune cell therapy, stem cell therapy, and gene therapy. Products include pCAR-19B cell autologous transfusion preparation for acute lymphoblastic leukaemia, C-4-29 cell preparation for myeloma, renal cell carcinoma, and C-13-60 for advanced solid cancer.

## Funding rounds

- Angel, Jul 28, 2016 — Forward Capital, Spring Fund

## Investors

- Forward Capital — Angel
- Spring Fund (https://capitalatlas.ai/funds/spring-fund) — Angel